[go: up one dir, main page]

AU2024304161A1 - Anti-fibril antibodies - Google Patents

Anti-fibril antibodies

Info

Publication number
AU2024304161A1
AU2024304161A1 AU2024304161A AU2024304161A AU2024304161A1 AU 2024304161 A1 AU2024304161 A1 AU 2024304161A1 AU 2024304161 A AU2024304161 A AU 2024304161A AU 2024304161 A AU2024304161 A AU 2024304161A AU 2024304161 A1 AU2024304161 A1 AU 2024304161A1
Authority
AU
Australia
Prior art keywords
fibril antibodies
fibril
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024304161A
Inventor
Daniel Christ
Jake HENRY
Jennifer Jackson
David Langley
Mark Brian Pepys
Jack William WADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immutrin Ltd
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of AU2024304161A1 publication Critical patent/AU2024304161A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2024304161A 2023-06-14 2024-06-13 Anti-fibril antibodies Pending AU2024304161A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2308884.2 2023-06-14
GB2308898.2 2023-06-14
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
PCT/EP2024/066449 WO2024256583A1 (en) 2023-06-14 2024-06-13 Anti-fibril antibodies

Publications (1)

Publication Number Publication Date
AU2024304161A1 true AU2024304161A1 (en) 2025-12-11

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024304161A Pending AU2024304161A1 (en) 2023-06-14 2024-06-13 Anti-fibril antibodies

Country Status (3)

Country Link
AU (1) AU2024304161A1 (en)
IL (1) IL325202A (en)
WO (1) WO2024256583A1 (en)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
DK3083681T3 (en) * 2013-12-20 2020-08-24 Neurimmune Holding Ag ANTIBODY-BASED THERAPY OF TRANSTHYRETIN (TTR) AMYLOIDOSIS AND HUMAN-DERIVED ANTIBODIES THEREOF
CN106574258B (en) * 2014-01-29 2021-03-30 Km生物医药股份公司 Anti-Transthyretin Humanized Antibody
EP3691447A4 (en) * 2017-10-06 2021-08-11 Prothena Biosciences Limited ANTI-TRANSTHYRETINE ANTIBODIES
JP2023548005A (en) * 2020-10-28 2023-11-15 ノヴォ ノルディスク アー／エス Anti-transthyretin antibody and its use

Also Published As

Publication number Publication date
IL325202A (en) 2026-02-01
WO2024256583A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
EP4324925A4 (en) Anti-c1s antibody
CA3268389A1 (en) Anti-ccr8 antibodies
EP4217396A4 (en) Novel anti-claudin18 antibodies
CA3246035A1 (en) Anti-par2 antibodies
CA3265092A1 (en) Humanized anti-nectin-4 antibodies
CA3297530A1 (en) Anti-trop2 antibodies
CA3291410A1 (en) Anti-fibril antibodies
AU2024304161A1 (en) Anti-fibril antibodies
CA3292361A1 (en) Anti-cathepsin-d antibodies
AU2024273407A1 (en) Anti-cathepsin-d antibodies
CA3291266A1 (en) Anti-il1rap antibodies
CA3276655A1 (en) Antibodies
CA3279302A1 (en) Anti-unc5c antibodies
CA3279198A1 (en) Anti-il-18bp antibodies
CA3271432A1 (en) Anti-beta-catenin antibodies
HK40115462A (en) Anti-par2 antibodies
HK40115074A (en) Galectin-10 antibodies
AU2022902836A0 (en) SARS-CoV-2 antibodies
AU2022902742A0 (en) Anti-CCR8 antibodies
CA3296531A1 (en) Antibody
HK40115703A (en) Zip12 antibody
HK40116629A (en) Anti-abcb1 antibodies
HK40105906A (en) Anti-hla-g antibodies
HK40110514A (en) Anti-csp antibodies
HK40102548A (en) Anti-sirp-alpha antibodies